Stocks

In June 2026, the “Magnificent Seven” erased a combined $2.3 trillion in market value as investors fretted over massive AI-related capital spending. Microsoft fell 20% over the month, Nvidia slid about 13%, and Apple and Amazon each declined around 8%. Amazon, Microsoft, Alphabet and Meta have pledged hundreds of billions of dollars for AI chip purchases and data-center construction, with some of the spending financed through borrowing. Industrywide AI-linked capital expenditures are projected to reach $700 billion in 2026, up roughly 70% year over year, pushing the group’s 12-month forward free-cash-flow outlook well below 2024 levels.

Despite a minor summer pullback to $195, Nvidia remains structurally undervalued at 29x P/E ahead of its 10x higher-performance Vera Rubin chip rollout. Backed by a historic $30 billion revenue-sharing AI factory deal in Batam, Indonesia, the semiconductor pioneer is aggressively expanding its sovereign cloud footprint to anchor multi-year growth.

Driven by an 11.89% monthly rally, Intel (INTC) is executing a historic transformation backed by a Zacks Rank #1 (Strong Buy) rating and $150 price targets. Leveraging advanced EMIB-T packaging cost advantages over TSMC and key host CPU wins for NVIDIA’s Rubin platforms, Intel's current 121x forward multiple is projected to compress to an attractive 56x by 2028.

Super Micro Computer (SMCI) shares tumbled 8.1% to $28.15 following a Taiwanese regulatory raid expanding an NVIDIA chip smuggling probe. While a low 11.85x forward P/E and a massive $39 billion AI backlog highlight immense fundamental value, persistent governance risks and recent $7 billion dilutive capital raises suggest technical caution.

Following a record-breaking $86.2 billion IPO, SpaceX (SPCX) surged 7.15% to $164.19 amid explosive options volume and fast-tracked Nasdaq-100 index inclusion. However, a massive $25 billion debt expansion to settle bridge loans highlights intense capital expenditures, introducing unique portfolio concentration risks for multi-asset investors.

Kernex Microsystems (India) posted FY26 net profit of ₹882.43 crore, up 75% year on year. In Q4, revenue reached ₹2,546 crore and EBITDA margin rose to 41.3%. The company has launched a postal ballot to seek shareholder approval to expand the board’s borrowing powers, increase remuneration for three whole-time directors and the managing director, and ratify related-party transactions.

Strategy said it has launched a Digital Credit Capital Framework, authorizing up to $1.25 billion in bitcoin sales to build a U.S. dollar reserve, fund preferred dividends, and service debt, while also approving $1 billion in common stock buybacks and $1 billion in preferred-security repurchases. The company also lifted the annual dividend rate on its STRC preferred stock to 12%. The steps eased investor concerns about liquidity and capital efficiency, pushing the stock up as much as 14% to roughly $94. Other bitcoin-linked names including Coinbase also rose, with improved risk sentiment lending support to the Nasdaq index.

MicroStrategy operating entity Strategy has launched a $1.25 billion Bitcoin monetization program to bolster its USD reserve, pay preferred dividends and interest, and support $1 billion of preferred and $1 billion of common stock buybacks. The move signals a potential shift from being Bitcoin’s largest corporate buyer to a sizable seller, after the company previously sold 32 BTC. At a $60,000 price, the authorization equates to more than 54,000 BTC, fueling concerns over balance-sheet health and the logic behind support for the stock price.

The U.S. National Highway Traffic Safety Administration formally closed its engineering analysis into a power-steering loss issue affecting about 376,241 2023 Model 3 and Model Y vehicles, citing Tesla’s over-the-air software recall and a measurable drop in owner complaints. Morgan Stanley and Barclays raised their Tesla Q2 delivery forecasts to 413,000 and about 418,000 vehicles, respectively, well above the prior consensus. Elon Musk also said xAI’s Grok 4.5 has begun internal private beta testing at Tesla and SpaceX, though the key drivers were reduced regulatory risk and higher delivery expectations.

Eli Lilly and Regeneron are among the first seven companies selected by the U.S. Food and Drug Administration for its PreCheck Pilot Program, CNBC reported. The initiative is aimed at accelerating regulatory reviews of new domestic pharmaceutical manufacturing facilities.